Myriad Genetics (MYGN) Tops Q2 EPS by 2c

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.26, $0.02 better than the analyst estimate of $0.24. Revenue for the quarter came in at $196.5 million versus the consensus estimate of $189.72 million.

GUIDANCE:

Myriad Genetics sees Q3 2017 EPS of $0.23-$0.25, versus the consensus of $0.25.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• Intuit holds investor day, reaffirms fiscal 2027 guidance